|
An Updated Assessment Of Ritonavir: A Protease Inhibitor
|
|
| Author:
|
NIVEDHA DURAISAMY, NAVEENA GOPAL, ANBARASU MAHENDIRAN, RAJESWARI RAJAMANI, POONGOTHAI SUNDRAMOORTHY, MUTHURAJ MUTHUVEL, VIVEKANANDHAN NATARAJAN, MOHANRAJ SUBRAMANIAN, SARAVANAKUMAR ARTHANARI
|
| Abstract:
|
Ritonavir, a protease inhibitor, is used to treat HIV/AIDS. Rarely does it function as a stand-alone antiviral medication, instead enhancing the antiviral effects of other protease inhibitors. Ritonavir was first created to block the HIV protease, however, research suggests that it also blocks cytochrome P450-3A4. Due to its manner of action, ritonavir is currently being studied for use in treating several types of cancer. It is additionally used in concert with other drugs to treat the Hepatitis C infection. The indications, dose, administration, adverse event profile, modes of action, toxicity, and contraindications of ritonavir are covered in this review. These observations can lead to new therapeutic indications of protease inhibitors to treat several cancers however, substantial extensive research is to be needed before clinical approval.
|
| Keyword:
|
Ritonavir, Protease inhibitor, antiviral.
|
| EOI:
|
-
|
| DOI:
|
https://doi.org/10.31838/ijpr/2023.15.04.002
|
| Download:
|
Request For Article
|
|
|